SOURCE: BioProgress PLC

May 23, 2005 02:01 ET

BioProgress Plc announces Appointment of CEO

Cambridgeshire -- (MARKET WIRE) -- May 23, 2005 --

Press Release                                                23 May 2005

                                 BioProgress plc

                        ("BioProgress" or "the Company")

                                CEO Appointment

BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the provider of innovative delivery mechanisms for the pharmaceutical oral dosage markets, announces the appointment of Richard Trevillion as Chief Executive Officer.

Mr Trevillion joined the Board as a Non-Executive Director in February 2005 and became interim Chief Executive at the end of April. He has a wide range of experience within the global healthcare and technology sectors, both as advisor and principal, and has been responsible for the development of a number of high growth technology businesses.

Commenting on his appointment, Richard Trevillion said: "I am delighted to accept the invitation of the Board to become CEO of BioProgress. The Company has a strong suite of technology and intellectual property, combined with a highly motivated team of professionals dedicated to the further commercialisation and development of the business. BioProgress has a strong balance sheet and international presence which we will use as a solid foundation to move the business forward to the next stages of growth and development."

The financial and strategic review will be completed by the end of this month, and the Board will provide shareholders with a report on the principal conclusions as soon as possible.

                                    - Ends -

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company's filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.

BioProgress plc
Richard Trevillion, CEO                        Tel: +44 (0) 1354 655674

UK Media enquiries:
Samantha Robbins                              Tel: +44 (0) 20 7398 7700    

US Investor enquiries:
Taylor Rafferty
Andrew Saunders                                    Tel: +1 212 889 4350   

                      This information is provided by RNS
            The company news service from the London Stock Exchange